CBT is a very rare minor cannabinoid that is gaining momentum. In fact, it is still difficult to purchase CBT as an analytical standard to identify and quantify CBT in biomass and extracts. CBT is not scheduled as a controlled substance.
In addition to Cannabicitran which branches from the CBC branch of the cannabinoid family tree, there is also a different cannabinoid molecule, Cannabitriol, which branches from the THC branch. This sometimes causes confusion because it too is commonly referenced by the same three letters in its acronym, “CBT.”
Molar mass: 314.46 g/mol
ChemSpider ID: 2859003
CBT is biosynthesized in cannabis in the classic olivetol series, which has been widely studied in scientific literature. Interestingly, both CBT molecules (cannabicitran and cannabitriol) are considered to be biosynthesized in the olivetol series. Cannabitriol is biosynthesized from THCA and cannabicitran from CBDA. Each molecule has a completely different molecular structure and molecular weight. (Hyperlink 1 and 2) While the structure of cannabitriol had been reported in 1970, it is cannabicitran that is commonly understood to be CBT in the hemp industry. It has been known to be part of cannabis sativa since 1974. (Hyperlink 3)
Very little is known about CBT (cannabicitran) itself and its potential medicinal properties. This rare compound has sparked the curiosity of researchers, scientists, and consumer products companies, and the demand for this compound is rapidly increasing to meet the demand for bioactive cannabinoids even though its expression in hemp plant chemovars is very rare. It is speculated that this cannabinoid contributes to the entourage effect.
PPM’s cannabicitran concentrate is 100% derived from hemp or biosynthesized from precursors, and its purity and molecular structure has been fully characterized by HPLC,GCMS, LC-MS, NMR, IR, melting point, and elemental analysis. All analytical test results demonstrated the high quality and purity of PPM’s premium CBT concentrates.
- Hyperlink 1: https://www.ncbi.nlm.nih.gov/pubmed/1253891
- Hyperlink 2: https://www.ncbi.nlm.nih.gov/pubmed/22041081
- Hyperlink 3: https://www.sciencedirect.com/science/article/abs/pii/S0031942200913621?via%3Dihub
All studies reported here have been published in the scientific peer-reviewed literature. From our survey and in our judgement, the articles cited are recent and relevant to the potential health and wellness benefits of rare cannabinoids but does not include all literature that exists. It must be noted that most clinical trials have been performed on the animal model or in vitro on cells. More research is required including human trials to demonstrate and understand efficacy, serving and dosing sizes, potential side effects, effects on at-risk populations, and drug interactions related to the use of minor cannabinoids.